Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q SummaryTradingView·Aug 14 at 11:21 AMCURX-1.90%
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga_article·Aug 5 at 07:05 AMJUNS+0.63%OFIX-0.57%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jun 30 at 07:05 AMUPC-4.12%DCOY+0.29%
Curanex shareholders back 1-for-10 to 1-for-50 reverse stock split to meet Nasdaq $1 bid rulePUBT·Jun 29 at 09:20 AMCURX-1.90%
Curanex Pharmaceuticals files draft information statement (Form PRE 14C)PUBT·Jun 18 at 04:12 PMCURX-1.90%
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga_article·Jun 9 at 04:06 PMCNTX+0.02%PMI-2.43%
07:37 ETWolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)prnewswire·May 18 at 06:37 AMCURX-1.90%
Curanex Reports GMP, Toxicology Milestones as Phyto-N Readies for Q4 2026 INDTradingView·May 14 at 08:23 AMCURX-1.90%
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | CURX Stock NewsStockTitan·May 13 at 11:55 PMCURX-1.90%
